


Rev. Add1
Rev. Add2

Schema



Accrual: 348 patients

1: Bone marrow specimen must be submitted to ECOG-ACRIN Leukemia Bank at MD Anderson Cancer Center for the central establishment of BCR/ABL status to confirm patient's eligibility for registration to Step 1 as outlined in Section 10.1. If a diagnosis of BCR-ABL positive ALL has been established locally, the patient may be registered to Step 1 without waiting for central confirmation. Peripheral Blood is only acceptable if there is circulating blasts.

2: Patients older than 70 and *younger unfit patients* are subject to modified Hyper-CVAD treatment only. All other patients will be treated with full Hyper-CVAD as outlined in Section 5. Type of planned Hyper-CVAD therapy is to be reported at time of registration.

3: At Step 2 Randomization, patients will be stratified by age (≤ 60 years vs 60-70 years vs > 70 years of age), TKI intended to receive (Dasatinib vs Ponatinib) and for patient age < 70 years, if patient is randomized to chemotherapy, investigators declaration of full or modified Hyper-CVAD protocol.

4: Patients must have achieved CR or CRi in order to begin intensification therapy.